Ocugen, Inc.
OCGN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.20 | -0.33 | -1.79 | -0.32 |
| FCF Yield | -3.80% | -9.39% | -4.43% | -4.27% |
| EV / EBITDA | -22.47 | -14.73 | -15.72 | -19.31 |
| Quality | ||||
| ROIC | -36.97% | -29.57% | -22.07% | -27.63% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.64 | 0.73 | 1.26 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.09% | 72.39% | 116.92% | 1,594,543.55% |
| Free Cash Flow Growth | 44.39% | -86.69% | 11.90% | -13.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.45 | 0.44 | 1.96 | 2.52 |
| Interest Coverage | -13.04 | -15.87 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |